The global Blood Screening Market is experiencing robust growth due to an
alarming prevalence of infectious diseases and an expanding geriatric population.
Age-related health conditions and a growing susceptibility to chronic illnesses among
the elderly have significantly increased the demand for blood screening. Additionally,
a consistent rise in blood donation programs and the frequency of blood transfusions
in hospitals and other healthcare settings further necessitate blood screening, driving
market growth.
However, the lack of standardization regarding blood transfusion procedures, a
complex regulatory approval framework, and a severe dearth of skilled manpower
continue to impede rapid market expansion, especially in developing economies.
Emerging alternative testing techniques like digital immunoassay are also expected
to pose a challenge to market growth in the near future.
Visit our Research Report:
https://www.fairfieldmarketresearch.com/report/blood-screening-market
Key Drivers of Market Growth
Mandatory blood screening for the presence of red cell antibodies and infectious
disease agents such as HIV-1 and -2, hepatitis virus, T. pallidum (syphilis), human Tlymphotropic virus (HTLV), T. Cruzi, and West Nile virus (WNV) are significant factors
contributing to the growth of the global blood screening market.
Opportunities are emerging with the introduction of microbiology screening,
multiplexing for HIV, HBV, and HCV, and pathogen reduction technology. Blood
screenings during pregnancy phases to detect possible prenatal abnormalities also
strongly encourage the demand for blood screening. Tests like western blot assay,
next-generation sequencing (NGS), and enzyme-linked immunosorbent assay
(ELISA) continue to uphold the market's growth prospects.
COVID-19 Pandemic and New Opportunities
Although blood screening related to transfusion and donation experienced a major
setback during the initial months of the pandemic, the overall long-term impact of the
pandemic is expected to favor the growth of the blood screening market. The
American Red Cross has pioneered blood screening covering blood, platelets, and
plasma for the presence of COVID-19 antibodies. Mandatory screening of donated
plasma for blood typing tests and infectious disease agents is likely to push market
growth.
The US Food and Drug Administration (FDA)’s emergency use authorization for
around 50 serological tests over the utilization of convalescent plasma in treating
hospitalized COVID-19 patients (April 2020) has been a solid booster to market
growth amid the pandemic. Continuous encouragement for plasma donation remains
a strong sustaining factor for the market.
Blood Banks and Screening Technologies
Blood banks are expected to remain the top end user, with hospitals also registering
substantial demand for blood screening tests. Reagents and kits are expected to
remain top-selling due to the critical need for specific, faster, and reliable detection of
transfusion transmissible infections (TTIs). This segment is driven by the rise in
blood transfusion and donation-related tests, further accelerated by the soaring
demand for serological testing amid the COVID-19 outbreak.
Among various blood screening technologies, including nucleic acid amplification
tests (NAT), ELISA, western blot assay, rapid tests, and NGS, NAT is expected to
remain sought-after due to its higher specificity and sensitivity for viral nucleic acid.
Regional Insights
North America, followed by Europe, is expected to remain the most significant
market in the blood screening landscape. The soaring demand for and response to
blood donation initiatives, higher chronic and infectious disease prevalence,
sophisticated healthcare infrastructure, and a thriving diagnostics space support
market growth in these regions. A strong presence of key market players also
benefits market growth.
The European market gains from a favorable regulatory environment. In Asia Pacific,
government initiatives signifying blood screening in diagnostics and rising awareness
about potential disease transmission through blood transfusion offer new
opportunities.
Recent Developments

Delfi Diagnostics: Launched an AI-enabled blood test capable of detecting
around 80% of lung cancer cases in their early stages.

NIBIB-funded Researchers: Developed a rapid blood screening test for
identifying a rare yet serious pregnancy condition, placenta accreta spectrum
(PAS) disorder.

Annals of Oncology (June 2021): Published research on a multi-cancer
blood screening test capable of detecting over 50 types of cancers before
symptoms appear and identifying potential cancer locations in the body.

Swedish Researchers: Discovered a novel blood screening test for prostate
cancer that reduces unnecessary MRI scans by 36%, cutting down biopsies
while delivering accurate results.

NHS England: Declared a severe shortage of blood screening test tubes and
vials, affecting patient care delivery temporarily.
Key Competitors
The competitive landscape of the global blood screening market includes prominent
players like GE Healthcare, Abbott Laboratories, Becton, Dickinson and Company,
Bio-Rad Laboratories, Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd,
Merck KGaA, PerkinElmer, Grifols, S.A., Ortho Clinical Diagnostics, Inc., bioMérieux,
Inc., Danaher Corporation, Siemens Healthineers, OriGene Technologies, Inc.,
DiaSorin, Demeditec Diagnostics GmbH, Boster Biological Technology, Cusabio
Technology LLC, Biovision, Inc., Immuno-Biological Laboratories Co., Ltd., BioTechne Corporation, BioAim Scientific Inc., Merck Millipore, GFE, Trinity Biotech,
Biomérieux, J Mitra & Co. Pvt. Ltd., and Beckman Coulter, Inc.